Rising rupee another risk for Indian pharma
Saturday, April 15, 2017, 7:26 AM
Pricing pressure and regulatory issues are not the only thing worrying executives of Indian pharmaceuticals companies. Weakening of the dollar versus the rupee in the first four-months of this calendar year is adding to the concerns; it might impact their earnings by five or six percent. An appreciation in the rupee versus the dollar means every-one of the latter yields less of the former.